Surgical intervention in patients with metastatic renal cancer: Metastasectomy and cytoreductive nephrectomy Journal Article
| Authors: | Russo, P.; O'brien, M. F. |
| Article Title: | Surgical intervention in patients with metastatic renal cancer: Metastasectomy and cytoreductive nephrectomy |
| Abstract: | For patients with metastatic renal cancer, prognostic factors defined in systemic therapy clinical trials stratify patients into good, intermediate, and poor risk groups with median survival varying from 4 to 13 months. These same factors also stratify patients whose renal cancers were initially resected completely and who then developed subsequent metastatic disease. Metastasectomy performed in low-risk patients was significantly associated with enhanced survival when compared with low-risk patients not undergoing metastasectomy. Two randomized, prospective clinical trials demonstrated a modest survival advantage of approximately 6 months for patients undergoing cytoreductive nephrectomy followed by interferon alfa-2b. Once effective systemic agents are developed, both metastasectomy and cytoreductive nephrectomy will play greater roles in consolidating clinical responses. © 2008 Elsevier Inc. All rights reserved. |
| Keywords: | cancer chemotherapy; cancer survival; treatment response; cancer surgery; survival rate; unclassified drug; clinical trial; review; sorafenib; interferon; sunitinib; cancer risk; drug efficacy; drug withdrawal; monotherapy; treatment duration; unspecified side effect; alpha interferon; cancer adjuvant therapy; cancer patient; neoadjuvant therapy; topotecan; drug megadose; antineoplastic agent; cytoreductive surgery; alpha2b interferon; interleukin 2; cancer immunotherapy; metastasis; risk factors; randomized controlled trials as topic; kidney neoplasms; nephrectomy; risk assessment; temsirolimus; cancer hormone therapy; postoperative complication; drug fatality; survival time; cancer regression; cytokine; cancer vaccine; monoclonal antibody g250; carcinoma, renal cell; heart infarction; neoplasm metastasis; flutamide; clear cell carcinoma; kidney cancer; everolimus; metastasectomy; interleukin 12; metastectomy; n methylformamide; renal cancer; heat shock protein; cytoreductive; heat shock protein peptide complex 96 |
| Journal Title: | Urologic Clinics of North America |
| Volume: | 35 |
| Issue: | 4 |
| ISSN: | 0094-0143 |
| Publisher: | W.B. Saunders Co-Elsevier Inc. |
| Date Published: | 2008-11-01 |
| Start Page: | 679 |
| End Page: | 686 |
| Language: | English |
| DOI: | 10.1016/j.ucl.2008.07.009 |
| PUBMED: | 18992621 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 13" - "Export Date: 17 November 2011" - "CODEN: UCNAD" - "Source: Scopus" |
